News
MOLN
5.08
-2.68%
-0.14
Weekly Report: what happened at MOLN last week (1216-1220)?
Weekly Report · 5h ago
Weekly Report: what happened at MOLN last week (1209-1213)?
Weekly Report · 12/16 09:12
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
NASDAQ · 12/13 14:55
Weekly Report: what happened at MOLN last week (1202-1206)?
Weekly Report · 12/09 09:12
Reported Sunday, Molecular Partners Reports Initial Efficacy And Safety Data For MP0533 In Phase 1/2a Study And Preclinical Success Of MP0621 At ASH 2024
Benzinga · 12/09 08:12
Molecular Partners AG Reports Acceptable Safety Profile and Initial Efficacy Data for MP0533 and MP0621 at ASH 2024
Barchart · 12/08 21:22
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
Barchart · 12/08 11:00
Weekly Report: what happened at MOLN last week (1125-1129)?
Weekly Report · 12/02 09:12
Weekly Report: what happened at MOLN last week (1118-1122)?
Weekly Report · 11/25 09:11
Weekly Report: what happened at MOLN last week (1111-1115)?
Weekly Report · 11/18 09:11
Weekly Report: what happened at MOLN last week (1104-1108)?
Weekly Report · 11/11 09:12
Molecular Partners Unveils Preclinical Proof-Of-Concept For CD3 Switch-DARPin T Cell Engager And Clinical Biomarker Insights For MP0317
Benzinga · 11/07 21:50
Molecular Partners’ Promising Pipeline and Financial Stability Justify Buy Rating
TipRanks · 11/05 05:35
Weekly Report: what happened at MOLN last week (1028-1101)?
Weekly Report · 11/04 09:12
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/01 12:11
Molecular Partners Advances Radio-DARPin Programs with Strong Funding
TipRanks · 10/31 20:33
For The FY24, At Constant Exchange Rates, Molecular Partners Reiterates Its Guidance For Total Expenses Of CHF 65–70 Million. ~CHF 7 Million Of This Will Be Non-Cash Effective Costs For Share-Based Payments, Pension Accounting And Depreciation. This Guidance Does Not Include Any Potential Receipts From R&D Collaborators
Benzinga · 10/31 20:07
Molecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M
TipRanks · 10/31 20:05
Molecular Partners Radio-DARPin Therapy Candidate MP0712 Supported By In Vivo Data Presented At The European Association Of Nuclear Medicine Congress; First-In-Human Start And Initial Clinical Data Expected In 2025
Benzinga · 10/31 20:05
MOLECULAR PARTNERS AG: FUNDED INTO 2027 WITH CASH AND SHORT-TERM TIME DEPOSITS OF CHF 143.6 MLN AS OF SEPTEMBER 30
Reuters · 10/31 20:00
More
Webull provides a variety of real-time MOLN stock news. You can receive the latest news about MOLECULAR PARTNERS AG through multiple platforms. This information may help you make smarter investment decisions.
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.